These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 38290250)

  • 1. Small molecule agents for triple negative breast cancer: Current status and future prospects.
    Ou Y; Wang M; Xu Q; Sun B; Jia Y
    Transl Oncol; 2024 Mar; 41():101893. PubMed ID: 38290250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
    Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
    Front Oncol; 2022; 12():919072. PubMed ID: 35795050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceritinib is a novel triple negative breast cancer therapeutic agent.
    Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
    Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
    Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions.
    Mai N; Abuhadra N; Jhaveri K
    Clin Breast Cancer; 2023 Dec; 23(8):784-799. PubMed ID: 37336650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research advances and new challenges in overcoming triple-negative breast cancer.
    Zong Y; Pegram M
    Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the therapeutic potential of ADC combination for triple-negative breast cancer.
    Lu L; Niu Z; Chao Z; Fu C; Chen K; Shi Y
    Cell Mol Life Sci; 2023 Nov; 80(12):350. PubMed ID: 37930428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.
    Yang R; Li Y; Wang H; Qin T; Yin X; Ma X
    Mol Biomed; 2022 Mar; 3(1):8. PubMed ID: 35243562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple negative breast cancer: approved treatment options and their mechanisms of action.
    Mandapati A; Lukong KE
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3701-3719. PubMed ID: 35976445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving management of metastatic triple negative breast cancer.
    Malhotra MK; Emens LA
    Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
    Schreiber AR; Andress M; Diamond JR
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
    [No Abstract]   [Full Text] [Related]  

  • 14. Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.
    You KS; Yi YW; Cho J; Park JS; Seong YS
    Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34207383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibody.
    Camirand A; Fadhil I; Luco AL; Ochietti B; Kremer RB
    Am J Cancer Res; 2013; 3(5):500-8. PubMed ID: 24224127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Therapies for Triple-Negative Breast Cancer.
    Lyons TG
    Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple negative breast cancer: looking for the missing link between biology and treatments.
    Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
    Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
    Lee A; Djamgoz MBA
    Cancer Treat Rev; 2018 Jan; 62():110-122. PubMed ID: 29202431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biology and Management of Patients With Triple-Negative Breast Cancer.
    Sharma P
    Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
    Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
    Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.